Pharmacotherapy in inherited and acquired ventricular arrhythmia in structurally normal adult hearts

References

• Tadros R, Cadrin-Tourigny J, Abadir S, et al. Pharmacotherapy for inherited arrhythmia syndromes: mechanistic basis, clinical trial evidence and practical application. Expert Rev Cardiovasc Ther. 2015;13(7):769–782.
   PubMed Web of Science ®Google Scholar
• Priori SG, Blomström-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC)endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Europace. 2015 Nov;17(11):1601–1687.
   PubMed Web of Science ®Google Scholar
• Priori SG, Wilde AA, Horie M, et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Heart Rhythm. 2013 Dec;10(12):1932–1963.
   PubMed Web of Science ®Google Scholar
• Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Circulation. 2018 Sep 25;138(13):e272–391.
   PubMed Web of Science ®Google Scholar
• Probst V, Veltmann C, Eckardt L, et al. Long-term prognosis of patients diagnosed with Brugada syndrome: results from the FINGER Brugada syndrome registry. Circulation. 2010 Feb 9;121(5):635–643.
   PubMed Web of Science ®Google Scholar
• Fauchier L, Isorni MA, Clementy N, et al. Prognostic value of programmed ventricular stimulation in Brugada syndrome according to clinical presentation: an updated meta-analysis of worldwide published data. Int J Cardiol. 2013 Oct 3;168(3):3027–3029.
   PubMed Web of Science ®Google Scholar
• Sieira J, Ciconte G, Conte G, et al. Long-term prognosis of drug-induced Brugada syndrome. Heart Rhythm. 2017;14(10):1427–1433.
   PubMed Web of Science ®Google Scholar
• Crotti L, Marcou CA, Tester DJ, et al. Spectrum and prevalence of mutations involving BrS1- through BrS12-susceptibility genes in a cohort of unrelated patients referred for Brugada syndrome genetic testing: implications for genetic testing. J Am Coll Cardiol. 2012 Oct 9;60(15):1410–1418.
   PubMed Web of Science ®Google Scholar
• Yan GX, Antzelevitch C. Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST-segment elevation. Circulation. 1999 Oct 12;100(15):1660–1666.
   PubMed Web of Science ®Google Scholar
• Ohgo T, Okamura H, Noda T, et al. Acute and chronic management in patients with Brugada syndrome associated with electrical storm of ventricular fibrillation. Heart Rhythm. 2007 Jun;4(6):695–700.
   PubMed Web of Science ®Google Scholar
• Kaneko Y, Horie M, Niwano S, et al. Electrical storm in patients with brugada syndrome is associated with early repolarization. Circ Arrhythm Electrophysiol. 2014 Dec;7(6):1122–1128.
   PubMed Web of Science ®Google Scholar
• Belhassen B, Glick A, Viskin S. Efficacy of quinidine in high-risk patients with Brugada syndrome. Circulation. 2004 Sep 28;110(13):1731–1737.
   PubMed Web of Science ®Google Scholar
• Anguera I, García-Alberola A, Dallaglio P, et al. shock reduction with long-term quinidine in patients with brugada syndrome and malignant ventricular arrhythmia episodes. J Am Coll Cardiol. 2016 05;67(13):1653–1654.
   PubMed Web of Science ®Google Scholar
• Andorin A, Gourraud J-B, Mansourati J, et al. The QUIDAM study: hydroquinidine therapy for the management of Brugada syndrome patients at high arrhythmic risk. Heart Rhythm. 2017;14(8):1147–1154.
   PubMed Web of Science ®Google Scholar
• Hermida J-S, Denjoy I, Clerc J, et al. Hydroquinidine therapy in Brugada syndrome. J Am Coll Cardiol. 2004 May 19;43(10):1853–1860.
   PubMed Web of Science ®Google Scholar
• Belhassen B, Rahkovich M, Michowitz Y, et al. Management of Brugada Syndrome: thirty-three-year experience using electrophysiologically guided therapy with class 1A antiarrhythmic drugs. Circ Arrhythm Electrophysiol. 2015 Dec;8(6):1393–1402.
   PubMed Web of Science ®Google Scholar
• Tsuchiya T, Ashikaga K, Honda T, et al. Prevention of ventricular fibrillation by cilostazol, an oral phosphodiesterase inhibitor, in a patient with Brugada syndrome. J Cardiovasc Electrophysiol. 2002 Jul;13(7):698–701.
   PubMed Web of Science ®Google Scholar
• Shinohara T, Ebata Y, Ayabe R, et al. Combination therapy of cilostazol and bepridil suppresses recurrent ventricular fibrillation related to J-wave syndromes. Heart Rhythm. 2014 Aug;11(8):1441–1445.
   PubMed Web of Science ®Google Scholar
• Abud A, Bagattin D, Goyeneche R, et al. Failure of cilostazol in the prevention of ventricular fibrillation in a patient with Brugada syndrome. J Cardiovasc Electrophysiol. 2006 Feb;17(2):210–212.
   PubMed Web of Science ®Google Scholar
• Paul G, Yusuf S, Sharma S. Unmasking of the Brugada syndrome phenotype during the acute phase of amiodarone infusion. Circulation. 2006 Sep 12;114(11):e489–91.
   PubMed Web of Science ®Google Scholar
• Nademanee K, Veerakul G, Mower M, et al. Defibrillator versus beta-blockers for unexplained death in Thailand (DEBUT): a randomized clinical trial. Circulation. 2003 May 6;107(17):2221–2226.
   PubMed Web of Science ®Google Scholar
• Postema PG, Wolpert C, Amin AS, et al. Drugs and Brugada syndrome patients: review of the literature, recommendations, and an up-to-date website (www.brugadadrugs.org). Heart Rhythm. 2009 Sep;6(9):1335–1341.
   PubMed Web of Science ®Google Scholar
• Moss AJ, Schwartz PJ, Crampton RS, et al. The long QT syndrome. Prospective longitudinal study of 328 families. Circulation. 1991 Sep;84(3):1136–1144.
   PubMed Web of Science ®Google Scholar
• Goldenberg I, Horr S, Moss AJ, et al. Risk for life-threatening cardiac events in patients with genotype-confirmed long-QT syndrome and normal-range corrected QT intervals. J Am Coll Cardiol. 2011 Jan 4;57(1):51–59.
   PubMed Web of Science ®Google Scholar
• Schwartz PJ, Crotti L. QTc behavior during exercise and genetic testing for the long-QT syndrome. Circulation. 2011 Nov 15;124(20):2181–2184.
   PubMed Web of Science ®Google Scholar
• Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Europace. 2011 Aug;13(8):1077–1109.
   Google Scholar
• Vincent GM, Schwartz PJ, Denjoy I, et al. High efficacy of beta-blockers in long-QT syndrome type 1: contribution of noncompliance and QT-prolonging drugs to the occurrence of beta-blocker treatment “failures”. Circulation. 2009 Jan 20;119(2):215–221.
   PubMed Web of Science ®Google Scholar
• Shimizu W, Antzelevitch C. Differential effects of beta-adrenergic agonists and antagonists in LQT1, LQT2 and LQT3 models of the long QT syndrome. J Am Coll Cardiol. 2000 Mar 1;35(3):778–786.
   PubMed Web of Science ®Google Scholar
• Chockalingam P, Crotti L, Girardengo G, et al. Not all beta-blockers are equal in the management of long QT syndrome types 1 and 2: higher recurrence of events under metoprolol. J Am Coll Cardiol. 2012 Nov 13;60(20):2092–2099.
   PubMedGoogle Scholar
• Steinberg C, Padfield GJ, Al-Sabeq B, et al. Experience with bisoprolol in long-QT1 and long-QT2 syndrome. J Interv Card Electrophysiol. 2016 Nov;47(2):163–170.
   Google Scholar
• Ruan Y, Liu N, Bloise R, et al. Gating properties of SCN5A mutations and the response to mexiletine in long-QT syndrome type 3 patients. Circulation. 2007 Sep 4;116(10):1137–1144.
   PubMed Web of Science ®Google Scholar
• Moss AJ, Windle JR, Hall WJ, et al. Safety and efficacy of flecainide in subjects with long QT-3 syndrome (DeltaKPQ mutation): a randomized, double-blind, placebo-controlled clinical trial. Ann Noninvasive Electrocardiol. 2005 Oct;10(4 Suppl):59–66.
   PubMed Web of Science ®Google Scholar
• Moss AJ, Zareba W, Schwarz KQ, et al. Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome. J Cardiovasc Electrophysiol. 2008 Dec;19(12):1289–1293.
   PubMed Web of Science ®Google Scholar
• Bos JM, Crotti L, Rohatgi RK, et al. Mexiletine shortens the QT interval in patients with potassium channel-mediated type 2 long QT syndrome. Circ Arrhythm Electrophysiol. 2019 May;12(5):e007280.
   PubMed Web of Science ®Google Scholar
• Nguyen H-L, Pieper GH, Wilders R. Andersen-Tawil syndrome: clinical and molecular aspects. Int J Cardiol. 2013 Dec 5;170(1):1–16.
   PubMed Web of Science ®Google Scholar
• Nattel S, Maguy A, Le Bouter S, et al. Arrhythmogenic ion-channel remodeling in the heart: heart failure, myocardial infarction, and atrial fibrillation. Physiol Rev. 2007 Apr;87(2):425–456.
   PubMed Web of Science ®Google Scholar
• Delannoy E, Sacher F, Maury P, et al. Cardiac characteristics and long-term outcome in Andersen-Tawil syndrome patients related to KCNJ2 mutation. Europace. 2013 Dec;15(12):1805–1811.
   Google Scholar
• Miyamoto K, Aiba T, Kimura H, et al. Efficacy and safety of flecainide for ventricular arrhythmias in patients with Andersen-Tawil syndrome with KCNJ2 mutations. Heart Rhythm. 2015 Mar;12(3):596–603.
   PubMed Web of Science ®Google Scholar
• Kuroda Y, Yuasa S, Watanabe Y, et al. Flecainide ameliorates arrhythmogenicity through NCX flux in Andersen-Tawil syndrome-iPS cell-derived cardiomyocytes. Biochem Biophys Rep. 2017;9:245–256.
   PubMedGoogle Scholar
• Bienias P, Kostera-Pruszczyk A, Miszczak-Knecht M, et al. Propafenone is not effective for severe ventricular arrhythmias in Andersen-Tawil syndrome. Arch Med Sci AMS. 2018 Jan;14(1):248–250.
   PubMed Web of Science ®Google Scholar
• Kannankeril PJ, Roden DM, Fish FA. Suppression of bidirectional ventricular tachycardia and unmasking of prolonged QT interval with verapamil in Andersen’s syndrome. J Cardiovasc Electrophysiol. 2004 Jan;15(1):119.
   PubMed Web of Science ®Google Scholar
• Splawski I, Timothy KW, Sharpe LM, et al. Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell. 2004 Oct 1;119(1):19–31.
   PubMed Web of Science ®Google Scholar
• Jacobs A, Knight BP, McDonald KT, et al. Verapamil decreases ventricular tachyarrhythmias in a patient with Timothy syndrome (LQT8). Heart Rhythm. 2006 Aug;3(8):967–970.
   PubMed Web of Science ®Google Scholar
• Shah DP, Baez-Escudero JL, Weisberg IL, et al. Ranolazine safely decreases ventricular and atrial fibrillation in Timothy syndrome (LQT8). Pacing Clin Electrophysiol. 2012 Mar;35(3):e62–4.
   PubMed Web of Science ®Google Scholar
• Gao Y, Xue X, Hu D, et al. Inhibition of late sodium current by mexiletine: a novel pharmotherapeutical approach in timothy syndrome. Circ Arrhythm Electrophysiol. 2013 Jun;6(3):614–622.
   PubMed Web of Science ®Google Scholar
• Dufendach KA, Timothy K, Ackerman MJ, et al. Clinical outcomes and modes of death in timothy syndrome: a multicenter international study of a rare disorder. JACC Clin Electrophysiol. 2018 Apr;4(4):459–466.
   PubMedGoogle Scholar
• Jervell A, Lange-Nielsen F. Congenital deaf-mutism, functional heart disease with prolongation of the Q-T interval and sudden death. Am Heart J. 1957 Jul;54(1):59–68.
   PubMed Web of Science ®Google Scholar
• Schwartz PJ, Spazzolini C, Crotti L, et al. The Jervell and Lange-Nielsen syndrome: natural history, molecular basis, and clinical outcome. Circulation. 2006 Feb 14;113(6):783–790.
   PubMed Web of Science ®Google Scholar
• Woosley RL, Black K, Heise CW, et al. CredibleMeds.org: what does it offer? Trends Cardiovasc Med. 2018 Feb;28(2):94–99.
   PubMed Web of Science ®Google Scholar
• Patel C, Antzelevitch C. Cellular basis for arrhythmogenesis in an experimental model of the SQT1 form of the short QT syndrome. Heart Rhythm. 2008 Apr;5(4):585–590.
   PubMed Web of Science ®Google Scholar
• Giustetto C, Schimpf R, Mazzanti A, et al. Long-term follow-up of patients with short QT syndrome. J Am Coll Cardiol. 2011 Aug 2;58(6):587–595.
   PubMed Web of Science ®Google Scholar
• Giustetto C, Di Monte F, Wolpert C, et al. Short QT syndrome: clinical findings and diagnostic-therapeutic implications. Eur Heart J. 2006 Oct;27(20):2440–2447.
   PubMed Web of Science ®Google Scholar
• Mazzanti A, Maragna R, Vacanti G, et al. Hydroquinidine prevents life-threatening arrhythmic events in patients with short QT syndrome. J Am Coll Cardiol. 2017 Dec 19;70(24):3010–3015.
   PubMed Web of Science ®Google Scholar
• Brugada R, Hong K, Dumaine R, et al. Sudden death associated with short-qt syndrome linked to mutations in HERG. Circulation. 2004 Jan 6;109(1):30–35.
   PubMed Web of Science ®Google Scholar
• Mizobuchi M, Enjoji Y, Yamamoto R, et al. Nifekalant and disopyramide in a patient with short QT syndrome: evaluation of pharmacological effects and electrophysiological properties. Pacing Clin Electrophysiol. 2008 Sep;31(9):1229–1232.
   PubMed Web of Science ®Google Scholar
• McPate MJ, Duncan RS, Witchel HJ, et al. Disopyramide is an effective inhibitor of mutant HERG K+ channels involved in variant 1 short QT syndrome. J Mol Cell Cardiol. 2006 Sep;41(3):563–566.
   PubMed Web of Science ®Google Scholar
• Bun -S-S, Maury P, Giustetto C, et al. Electrical storm in short-QT syndrome successfully treated with Isoproterenol. J Cardiovasc Electrophysiol. 2012 Sep;23(9):1028–1030.
   PubMed Web of Science ®Google Scholar
• Priori SG, Napolitano C, Tiso N, et al. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation. 2001 Jan 16;103(2):196–200.
   PubMed Web of Science ®Google Scholar
• Cerrone M, Noujaim SF, Tolkacheva EG, et al. Arrhythmogenic mechanisms in a mouse model of catecholaminergic polymorphic ventricular tachycardia. Circ Res. 2007 Nov 9;101(10):1039–1048.
   PubMed Web of Science ®Google Scholar
• Hayashi M, Denjoy I, Extramiana F, et al. Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia. Circulation. 2009 May 12;119(18):2426–2434.
   PubMed Web of Science ®Google Scholar
• Leren IS, Saberniak J, Majid E, et al. Nadolol decreases the incidence and severity of ventricular arrhythmias during exercise stress testing compared with β1-selective β-blockers in patients with catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm. 2016 Feb;13(2):433–440.
   PubMed Web of Science ®Google Scholar
• van der Werf C, Kannankeril PJ, Sacher F, et al. Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. J Am Coll Cardiol. 2011 May 31;57(22):2244–2254.
   PubMed Web of Science ®Google Scholar
• Padfield GJ, AlAhmari L, Lieve KVV, et al. Flecainide monotherapy is an option for selected patients with catecholaminergic polymorphic ventricular tachycardia intolerant of β-blockade. Heart Rhythm. 2016 Feb;13(2):609–613.
   PubMed Web of Science ®Google Scholar
• Khoury A, Marai I, Suleiman M, et al. Flecainide therapy suppresses exercise-induced ventricular arrhythmias in patients with CASQ2-associated catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm. 2013 Nov;10(11):1671–1675.
   PubMed Web of Science ®Google Scholar
• Watanabe H, van der Werf C, Roses-Noguer F, et al. Effects of flecainide on exercise-induced ventricular arrhythmias and recurrences in genotype-negative patients with catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm. 2013 Apr;10(4):542–547.
   PubMed Web of Science ®Google Scholar
• Rosso R, Kalman JM, Rogowski O, et al. Calcium channel blockers and beta-blockers versus beta-blockers alone for preventing exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm. 2007 Sep;4(9):1149–1154.
   PubMed Web of Science ®Google Scholar
• Marx A, Lange B, Nalenz C, et al. A 35-year effective treatment of catecholaminergic polymorphic ventricular tachycardia with propafenone. HeartRhythm Case Rep. 2019 Feb;5(2):74–77.
   PubMedGoogle Scholar
• Vaksmann G, Klug D. Efficacy of ivabradine to control ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia. Pacing Clin Electrophysiol. 2018;41(10):1378–1380.
   PubMed Web of Science ®Google Scholar
• Sedej S, Heinzel FR, Walther S, et al. Na+-dependent SR Ca2+ overload induces arrhythmogenic events in mouse cardiomyocytes with a human CPVT mutation. Cardiovasc Res. 2010 Jul 1;87(1):50–59.
   PubMed Web of Science ®Google Scholar
• van der Werf C, Lieve KV, Bos JM, et al. Implantable cardioverter-defibrillators in previously undiagnosed patients with catecholaminergic polymorphic ventricular tachycardia resuscitated from sudden cardiac arrest. Eur Heart J. 2019 May 30.
   PubMed Web of Science ®Google Scholar
• Tikkanen JT, Anttonen O, Junttila MJ, et al. Long-term outcome associated with early repolarization on electrocardiography. N Engl J Med. 2009 Dec 24;361(26):2529–2537.
   PubMed Web of Science ®Google Scholar
• Wu S-H, Lin -X-X, Cheng Y-J, et al. Early repolarization pattern and risk for arrhythmia death: a meta-analysis. J Am Coll Cardiol. 2013 Feb 12;61(6):645–650.
   PubMed Web of Science ®Google Scholar
• Haïssaguerre M, Derval N, Sacher F, et al. Sudden cardiac arrest associated with early repolarization. N Engl J Med. 2008 May 8;358(19):2016–2023.
   PubMed Web of Science ®Google Scholar
• Rosso R, Kogan E, Belhassen B, et al. J-point elevation in survivors of primary ventricular fibrillation and matched control subjects: incidence and clinical significance. J Am Coll Cardiol. 2008 Oct 7;52(15):1231–1238.
   PubMed Web of Science ®Google Scholar
• Koncz I, Gurabi Z, Patocskai B, et al. Mechanisms underlying the development of the electrocardiographic and arrhythmic manifestations of early repolarization syndrome. J Mol Cell Cardiol. 2014;68:20–28.
   PubMed Web of Science ®Google Scholar
• Malhi N, So PP, Cheung CC, et al. Early repolarization pattern inheritance in the Cardiac Arrest Survivors With Preserved Ejection Fraction Registry (CASPER). JACC Clin Electrophysiol. 2018 Nov;4(11):1473–1479.
   PubMedGoogle Scholar
• Haïssaguerre M, Sacher F, Nogami A, et al. Characteristics of recurrent ventricular fibrillation associated with inferolateral early repolarization role of drug therapy. J Am Coll Cardiol. 2009 Feb 17;53(7):612–619.
   PubMed Web of Science ®Google Scholar
• Aizawa Y, Chinushi M, Hasegawa K, et al. Electrical storm in idiopathic ventricular fibrillation is associated with early repolarization. J Am Coll Cardiol. 2013 Sep 10;62(11):1015–1019.
   PubMed Web of Science ®Google Scholar
• Iguchi K, Noda T, Kamakura S, et al. Beneficial effects of cilostazol in a patient with recurrent ventricular fibrillation associated with early repolarization syndrome. Heart Rhythm. 2013 Apr;10(4):604–606.
   PubMed Web of Science ®Google Scholar
• Yamada T, Litovsky SH, Kay GN. The left ventricular ostium: an anatomic concept relevant to idiopathic ventricular arrhythmias. Circ Arrhythm Electrophysiol. 2008 Dec;1(5):396–404.
   PubMed Web of Science ®Google Scholar
• Morady F, Kadish AH, DiCarlo L, et al. Long-term results of catheter ablation of idiopathic right ventricular tachycardia. Circulation. 1990 Dec;82(6):2093–2099.
   PubMed Web of Science ®Google Scholar
• Marchlinski FE, Deely MP, Zado ES. Sex-specific triggers for right ventricular outflow tract tachycardia. Am Heart J. 2000 Jun;139(6):1009–1013.
   PubMed Web of Science ®Google Scholar
• Tada H, Hiratsuji T, Naito S, et al. Prevalence and characteristics of idiopathic outflow tract tachycardia with QRS alteration following catheter ablation requiring additional radiofrequency ablation at a different point in the outflow tract. Pacing Clin Electrophysiol. 2004 Sep;27(9):1240–1249.
   PubMed Web of Science ®Google Scholar
• Yamada T, McElderry HT, Doppalapudi H, et al. Idiopathic ventricular arrhythmias originating from the aortic root prevalence, electrocardiographic and electrophysiologic characteristics, and results of radiofrequency catheter ablation. J Am Coll Cardiol. 2008 Jul 8;52(2):139–147.
   PubMed Web of Science ®Google Scholar
• Iwai S, Cantillon DJ, Kim RJ, et al. Right and left ventricular outflow tract tachycardias: evidence for a common electrophysiologic mechanism. J Cardiovasc Electrophysiol. 2006 Oct;17(10):1052–1058.
   PubMed Web of Science ®Google Scholar
• Gill JS, Blaszyk K, Ward DE, et al. Verapamil for the suppression of idiopathic ventricular tachycardia of left bundle branch block-like morphology. Am Heart J. 1993 Nov;126(5):1126–1133.
   PubMed Web of Science ®Google Scholar
• Krittayaphong R, Bhuripanyo K, Punlee K, et al. Effect of atenolol on symptomatic ventricular arrhythmia without structural heart disease: a randomized placebo-controlled study. Am Heart J. 2002 Dec;144(6):e10.
   PubMedGoogle Scholar
• Ling Z, Liu Z, Su L, et al. Radiofrequency ablation versus antiarrhythmic medication for treatment of ventricular premature beats from the right ventricular outflow tract: prospective randomized study. Circ Arrhythm Electrophysiol. 2014 Apr;7(2):237–243.
   PubMed Web of Science ®Google Scholar
• Cronin EM, Bogun FM, Maury P, et al. HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias. Europace. 2019;2019(May):10.
   Google Scholar
• Ouyang F, Mathew S, Wu S, et al. Ventricular arrhythmias arising from the left ventricular outflow tract below the aortic sinus cusps: mapping and catheter ablation via transseptal approach and electrocardiographic characteristics. Circ Arrhythm Electrophysiol. 2014 Jun;7(3):445–455.
   PubMed Web of Science ®Google Scholar
• Belhassen B, Viskin S. Idiopathic ventricular tachycardia and fibrillation. J Cardiovasc Electrophysiol. 1993 Jun;4(3):356–368.
   PubMed Web of Science ®Google Scholar
• Ohe T, Shimomura K, Aihara N, et al. Idiopathic sustained left ventricular tachycardia: clinical and electrophysiologic characteristics. Circulation. 1988 Mar;77(3):560–568.
   PubMed Web of Science ®Google Scholar
• Liu Y, Fang Z, Yang B, et al. Catheter ablation of fascicular ventricular tachycardia: long-term clinical outcomes and mechanisms of recurrence. Circ Arrhythm Electrophysiol. 2015 Dec;8(6):1443–1451.
   PubMed Web of Science ®Google Scholar
• Doppalapudi H, Yamada T, McElderry HT, et al. Ventricular tachycardia originating from the posterior papillary muscle in the left ventricle: a distinct clinical syndrome. Circ Arrhythm Electrophysiol. 2008 Apr;1(1):23–29.
   PubMed Web of Science ®Google Scholar
• Santoro F, Di Biase L, Hranitzky P, et al. Ventricular fibrillation triggered by PVCs from papillary muscles: clinical features and ablation. J Cardiovasc Electrophysiol. 2014 Nov;25(11):1158–1164.
   PubMed Web of Science ®Google Scholar
• Yamada T, Doppalapudi H, McElderry HT, et al. Electrocardiographic and electrophysiological characteristics in idiopathic ventricular arrhythmias originating from the papillary muscles in the left ventricle: relevance for catheter ablation. Circ Arrhythm Electrophysiol. 2010 Aug;3(4):324–331.
   PubMed Web of Science ®Google Scholar
• Tada H, Ito S, Naito S, et al. Idiopathic ventricular arrhythmia arising from the mitral annulus: a distinct subgroup of idiopathic ventricular arrhythmias. J Am Coll Cardiol. 2005 Mar 15;45(6):877–886.
   PubMed Web of Science ®Google Scholar
• Viskin S, Belhassen B. Idiopathic ventricular fibrillation. Am Heart J. 1990 Sep;120(3):661–671.
   PubMed Web of Science ®Google Scholar
• Visser M, van der Heijden JF, van der Smagt JJ, et al. Long-term outcome of patients initially diagnosed with idiopathic ventricular fibrillation: a descriptive study. Circ Arrhythm Electrophysiol. 2016;9:10.
   Web of Science ®Google Scholar
• Aizawa Y, Sato M, Ohno S, et al. Circadian pattern of fibrillatory events in non-Brugada-type idiopathic ventricular fibrillation with a focus on J waves. Heart Rhythm. 2014 Dec;11(12):2261–2266.
   PubMed Web of Science ®Google Scholar
• Belhassen B, Glick A, Viskin S. Excellent long-term reproducibility of the electrophysiologic efficacy of quinidine in patients with idiopathic ventricular fibrillation and Brugada syndrome. Pacing Clin Electrophysiol. 2009 Mar;32(3):294–301.
   PubMed Web of Science ®Google Scholar
• Belhassen B, Shapira I, Shoshani D, et al. Idiopathic ventricular fibrillation: inducibility and beneficial effects of class I antiarrhythmic agents. Circulation. 1987 Apr;75(4):809–816.
   PubMed Web of Science ®Google Scholar
• Nogami A. Purkinje-related arrhythmias part ii: polymorphic ventricular tachycardia and ventricular fibrillation. Pacing Clin Electrophysiol. 2011 Aug;34(8):1034–1049.
   PubMed Web of Science ®Google Scholar
• Scheinman MM. Role of the His-Purkinje system in the genesis of cardiac arrhythmia. Heart Rhythm. 2009 Jul;6(7):1050–1058.
   PubMed Web of Science ®Google Scholar
• Haïssaguerre M, Shah DC, Jaïs P, et al. Role of Purkinje conducting system in triggering of idiopathic ventricular fibrillation. Lancet. 2002 Feb 23;359(9307):677–678.
   PubMed Web of Science ®Google Scholar
• Nogami A, Sugiyasu A, Kubota S, et al. Mapping and ablation of idiopathic ventricular fibrillation from the Purkinje system. Heart Rhythm. 2005 Jun;2(6):646–649.
   PubMed Web of Science ®Google Scholar
• Haïssaguerre M, Shoda M, Jaïs P, et al. Mapping and ablation of idiopathic ventricular fibrillation. Circulation. 2002 Aug 20;106(8):962–967.
   PubMed Web of Science ®Google Scholar
• Knecht S, Sacher F, Wright M, et al. Long-term follow-up of idiopathic ventricular fibrillation ablation: a multicenter study. J Am Coll Cardiol. 2009 Aug 4;54(6):522–528.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs implantable defibrillator study. Cardiac arrest study hamburg. canadian implantable defibrillator study. Eur Heart J. 2000 Dec;21(24):2071–2078.
   PubMed Web of Science ®Google Scholar
• Meissner MD, Lehmann MH, Steinman RT, et al. Ventricular fibrillation in patients without significant structural heart disease: a multicenter experience with implantable cardioverter-defibrillator therapy. J Am Coll Cardiol. 1993 May;21(6):1406–1412.
   PubMed Web of Science ®Google Scholar
• Leenhardt A, Glaser E, Burguera M, et al. Short-coupled variant of torsade de pointes. A new electrocardiographic entity in the spectrum of idiopathic ventricular tachyarrhythmias. Circulation. 1994 Jan;89(1):206–215.
   PubMed Web of Science ®Google Scholar
• Alders M, Koopmann TT, Christiaans I, et al. Haplotype-sharing analysis implicates chromosome 7q36 harboring DPP6 in familial idiopathic ventricular fibrillation. Am J Hum Genet. 2009 Apr;84(4):468–476.
   PubMed Web of Science ®Google Scholar
• Xiao L, Koopmann TT, Ördög B, et al. Unique cardiac Purkinje fiber transient outward current β-subunit composition: a potential molecular link to idiopathic ventricular fibrillation. Circ Res. 2013 May 10;112(10):1310–1322.
   PubMed Web of Science ®Google Scholar
• Laksman Z, Barichello S, Roston TM, et al. Acute management of ventricular arrhythmia in patients with suspected inherited heart rhythm disorders. JACC Clin Electrophysiol. 2019 Mar;5(3):267–283.
   PubMedGoogle Scholar
• Eisenberg SJ, Scheinman MM, Dullet NK, et al. Sudden cardiac death and polymorphous ventricular tachycardia in patients with normal QT intervals and normal systolic cardiac function. Am J Cardiol. 1995 Apr 1;75(10):687–692.
   PubMed Web of Science ®Google Scholar
• Godinho AR, Frutuoso C, Vasconcelos M, et al. Arrhythmic storm: short-coupled variant torsade de pointes. Rev Port Cardiol. 2016 May;35(5):307.e1–5.
   PubMedGoogle Scholar
• Bogaard K, van der Steen MS, Tan HL, et al. Short-coupled variant of torsade de pointes. Neth Heart J. 2008 Aug;16(7–8):246–249.
   PubMed Web of Science ®Google Scholar
• Malhi N, Cheung CC, Deif B, et al. Challenge and impact of quinidine access in sudden death syndromes: a national experience. JACC Clin Electrophysiol. 2019 Mar;5(3):376–382.
   PubMedGoogle Scholar